+

WO1999006561A3 - Chemokine receptor ccr8 dna and uses thereof - Google Patents

Chemokine receptor ccr8 dna and uses thereof Download PDF

Info

Publication number
WO1999006561A3
WO1999006561A3 PCT/US1998/015730 US9815730W WO9906561A3 WO 1999006561 A3 WO1999006561 A3 WO 1999006561A3 US 9815730 W US9815730 W US 9815730W WO 9906561 A3 WO9906561 A3 WO 9906561A3
Authority
WO
WIPO (PCT)
Prior art keywords
ccr8
hiv
infection
human
chemokine receptor
Prior art date
Application number
PCT/US1998/015730
Other languages
French (fr)
Other versions
WO1999006561A2 (en
Inventor
H Lee Tiffany
Philip M Murphy
Edward A Berger
Ghalib Alkhatib
Hernan Bazan
Tom I Bonner
Laura Lautens
Original Assignee
Us Health
H Lee Tiffany
Philip M Murphy
Edward A Berger
Ghalib Alkhatib
Hernan Bazan
Tom I Bonner
Laura Lautens
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Health, H Lee Tiffany, Philip M Murphy, Edward A Berger, Ghalib Alkhatib, Hernan Bazan, Tom I Bonner, Laura Lautens filed Critical Us Health
Priority to AU86695/98A priority Critical patent/AU8669598A/en
Publication of WO1999006561A2 publication Critical patent/WO1999006561A2/en
Publication of WO1999006561A3 publication Critical patent/WO1999006561A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7158—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for chemokines
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

The susceptibility of target to human immunodeficiency virus (HIV) infection depends on cell surface expression of the human CD4 molecule and CC chemokine receptor 8. CCR8 is a member of the 7-transmembrane segment superfamily of G-protein-coupled cell surface molecules. CCR8 plays an essential role in the membrane fusion step of infection by diverse HIV isolates. The establishment of stable, nonhuman cell lines and transgenic mammals having cells that coexpress human CD4 and CCR8 provides valuable tools for the continuing research of HIV infection. In addition, antibodies which bind to CCR8, CCR8 variants, and CCR8-binding agents, capable of blocking membrane fusion between HIV and target cells represent potential anti-HIV therapeutics.
PCT/US1998/015730 1997-07-29 1998-07-29 Chemokine receptor ccr8 dna and uses thereof WO1999006561A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU86695/98A AU8669598A (en) 1997-07-29 1998-07-29 Chemokine receptor ccr8 dna and uses thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5409497P 1997-07-29 1997-07-29
US60/054,094 1997-07-29

Publications (2)

Publication Number Publication Date
WO1999006561A2 WO1999006561A2 (en) 1999-02-11
WO1999006561A3 true WO1999006561A3 (en) 1999-04-22

Family

ID=21988764

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1998/015730 WO1999006561A2 (en) 1997-07-29 1998-07-29 Chemokine receptor ccr8 dna and uses thereof

Country Status (2)

Country Link
AU (1) AU8669598A (en)
WO (1) WO1999006561A2 (en)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7160546B2 (en) 1995-06-06 2007-01-09 Human Genome Sciences, Inc. Human G-protein chemokine receptor (CCR5) HDGNR10
US7175988B2 (en) 2001-02-09 2007-02-13 Human Genome Sciences, Inc. Human G-protein Chemokine Receptor (CCR5) HDGNR10
US7393934B2 (en) 2001-12-21 2008-07-01 Human Genome Sciences, Inc. Human G-protein chemokine receptor (CCR5) HDGNR10
US7501123B2 (en) 2004-03-12 2009-03-10 Human Genome Sciences, Inc. Human G-protein chemokine receptor (CCR5) HDGNR10

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6743594B1 (en) 1995-06-06 2004-06-01 Human Genome Sciences, Inc. Methods of screening using human G-protein chemokine receptor HDGNR10 (CCR5)
FR2771423A1 (en) * 1997-11-21 1999-05-28 Transgene Sa Recombinant viral vector expressing polypeptide that inhibits viral binding
US6762341B2 (en) 2000-02-10 2004-07-13 Schering Corporation Uses of mammalian CCR8 receptors and related reagents
WO2001058484A2 (en) * 2000-02-10 2001-08-16 Schering Corporation Novel uses of mammalian ccr8 receptors and related reagents
AU2001296270A1 (en) * 2000-09-15 2002-03-26 Genaissance Pharmaceuticals, Inc. Haplotypes of the ccr8 gene
JP2005504503A (en) * 2001-02-06 2005-02-17 インサイト・ゲノミックス・インコーポレイテッド Receptors and membrane-related proteins
AU2003229753A1 (en) * 2002-05-13 2003-11-11 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with chemokine receptor 8 (ccr8)
WO2007044756A2 (en) * 2005-10-11 2007-04-19 Icos Corporation Monoclonal antibodies recognizing human ccr8
EP3458473B8 (en) * 2016-05-16 2022-08-17 Checkmab S.R.L. Markers selectively deregulated in tumor-infiltrating regulatory t cells.
US20220064312A1 (en) * 2018-12-27 2022-03-03 Shionogi & Co., Ltd. Novel Anti-CCR8 Antibody
CA3128971A1 (en) 2019-03-08 2020-09-17 Klinikum Der Universitat Munchen Ccr8 expressing lymphocytes for targeted tumor therapy
MX2023004349A (en) * 2020-10-16 2023-08-22 Lanova Medicines Ltd Anti-ccr8 monoclonal antibodies and uses thereof.

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996039434A1 (en) * 1995-06-05 1996-12-12 Human Genome Sciences, Inc. Human g-protein receptor hgber32

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996039434A1 (en) * 1995-06-05 1996-12-12 Human Genome Sciences, Inc. Human g-protein receptor hgber32

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
BERNARDINI, G. ET AL.: "Identification of the CC chemokines TARC and macrophage inflammatory protein-1 beta as novel functional ligands for the CCR8 receptor", EUROPEAN JOURNAL OF IMMUNOLOGY, vol. 28, no. 2, February 1998 (1998-02-01), pages 582 - 588, XP002092743 *
HORUK, R. ET AL.: "The CC chemokine I-309 inhibits CCR8-dependent infection by diverse HIV-1 strains", JOURNAL OF BIOLOGICAL CHEMISTRY. (MICROFILMS), vol. 273, no. 1, 2 January 1998 (1998-01-02), MD US, pages 386 - 391, XP002092742 *
ROOS, R. STUBER ET AL.: "Identification of CCR8, the receptor for the human CC Chemokine I-309", JOURNAL OF BIOLOGICAL CHEMISTRY (MICROFILMS), vol. 272, no. 28, 11 July 1997 (1997-07-11), MD US, pages 17251 - 17257, XP002092741 *
RUCKER, J. ET AL.: "Utilization of chemokine receptors, orphan receptors, and Herpesvirus-encoded receptors by diverse Human and Simian Immunodeficiency Viruses", JOURNAL OF VIROLOGY., vol. 71, no. 12, December 1997 (1997-12-01), ICAN SOCIETY FOR MICROBIOLOGY US, pages 8999 - 9007, XP002092744 *
SAMSON, M. ET AL.: "Molecular cloning and chromosomal mapping of a novel human gene, ChemR1, expressed in T lymphocytes and polymorphonuclear cells and encoding a putative chemokine receptor", EUROPEAN JOURNAL OF IMMUNOLOGY, vol. 26, 1996, pages 3021 - 3028, XP002092740 *
TIFFANY, H. L. ET AL.: "A model system for inducible expression of the CC chemokine receptors CCR1, CCR3 and CCR8", JOURNAL OF LEUKOCYTE BIOLOGY, no. suppl, December 1997 (1997-12-01), pages 7, XP002092745 *
TIFFANY, H. L. ET AL.: "Identification of CCR8: a human monocyte and thymus receptor for the CC chemokine I-309", JOURNAL OF EXPERIMENTAL MEDICINE, vol. 186, no. 1, 7 July 1997 (1997-07-07), pages 165 - 170, XP002092538 *
ZABALLOS A ET AL: "MOLECULAR CLONING AND RNA EXPRESSION OF TWO NEW HUMAN CHEMOKINE RECEPTOR-LIKE GENES", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 227, no. 3, 23 October 1996 (1996-10-23), pages 846 - 853, XP002055490 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7160546B2 (en) 1995-06-06 2007-01-09 Human Genome Sciences, Inc. Human G-protein chemokine receptor (CCR5) HDGNR10
US7175988B2 (en) 2001-02-09 2007-02-13 Human Genome Sciences, Inc. Human G-protein Chemokine Receptor (CCR5) HDGNR10
US7393934B2 (en) 2001-12-21 2008-07-01 Human Genome Sciences, Inc. Human G-protein chemokine receptor (CCR5) HDGNR10
US7501123B2 (en) 2004-03-12 2009-03-10 Human Genome Sciences, Inc. Human G-protein chemokine receptor (CCR5) HDGNR10

Also Published As

Publication number Publication date
WO1999006561A2 (en) 1999-02-11
AU8669598A (en) 1999-02-22

Similar Documents

Publication Publication Date Title
WO1997045543A3 (en) Cc chemokine receptor 5, antibodies thereto, transgenic animals
WO1999006561A3 (en) Chemokine receptor ccr8 dna and uses thereof
Trkola et al. CD4-dependent, antibody-sensitive interactions between HIV-1 and its co-receptor CCR-5
DE69029036D1 (en) SPECIFIC REAGENTS FOR AIDS THERAPY
Mizuochi et al. Diversity of oligosaccharide structures on the envelope glycoprotein gp 120 of human immunodeficiency virus 1 from the lymphoblastoid cell line H9. Presence of complex-type oligosaccharides with bisecting N-acetylglucosamine residues.
Hirsch et al. Therapy for human immunodeficiency virus infection
WO1998018826A3 (en) Anti-CCR5 antibodies and methods of use therefor
AU3401289A (en) Endowing cells with antibody specificity
CA2140663A1 (en) Compounds which inhibit hiv replication
WO2003089624A3 (en) Fc receptor homolog, reagents, and uses thereof
CA2069960A1 (en) Bispecific heteroantibodies with dual effector functions
Shokat et al. Redirecting the immune response: ligand-mediated immunogenicity
Morikawa et al. Expression of HIV-1 gp120 and human soluble CD4 by recombinant baculoviruses and their interaction in vitro
WO2002079186A3 (en) Aminopiperidine derivatives as modulators of chemokine receptor activity
WO2003016333A3 (en) Virus coat protein/receptor chimeras and methods of use
WO1998009642A3 (en) Therapeutic chemokine antagonists
WO1997046697A3 (en) Antibodies against a complex of cd4 and a chemokine receptor domain, and their use against hiv infections
CA2169603A1 (en) Retrovirus from the hiv group and its use
WO2002068654A3 (en) Recombinant poxvirus for chimeric proteins of the human immunodeficiency virus
REDDY et al. Elevated soluble interleukin-2 receptor levels in serum of human immunodeficiency virus infected populations
JP2002538814A5 (en)
Morikawa et al. Reduction in CD4 binding affinity associated with removal of a single glycosylation site in the external glycoprotein of HIV-2
Douvas et al. Cross-Reactivity between Autoimmune Anti-Ul snRNP Antibodies and Neutralizing Epitopes of HIV-1 gp 120/41
WO1998044098A3 (en) Strl33, a human fusion accessory factor associated with hiv infection
WO1995007716A1 (en) Pharmaceutical composition comprising monoclonal antibodies against the interferon receptor, with neutralizing activity against type i interferon

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
NENP Non-entry into the national phase

Ref country code: KR

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: CA

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载